Fraser Craig
Clinical Trial Assistant
Trials
Early diagnosis is central to improving outcomes for patients with cancer. For cancers without specific risk factors, or with no screening programs are difficult to diagnose and patients often present with non-specific symptoms. Unfortunately this means that these patients are often diagnosed late on in the development of the disease and treatment options are reduced.
INFERENCE
EMBOL1 Study
A Performance Evaluation of The Lumiradx Point of Care D Dimer Assay AS AN Aid in the Diagnosis and Assessment of VTE (EMBOL1)
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
NOVEL Study
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)
SABER Study
Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)